סימבקסון 10

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

SIMVASTATIN

Pieejams no:

DEXCEL PHARMA TECHNOLOGIES LTD

ATĶ kods:

C10AA01

Zāļu forma:

קפליות

Kompozīcija:

SIMVASTATIN 10 MG

Ievadīšanas:

פומי

Receptes veids:

מרשם נדרש

Ražojis:

DEXCEL LTD, ISRAEL

Ārstniecības grupa:

SIMVASTATIN

Ārstniecības joma:

SIMVASTATIN

Ārstēšanas norādes:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Produktu pārskats:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Autorizācija datums:

2020-04-30